Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea

Summary

This study is being conducted to evaluate the safety and tolerability of crofelemer 125 mg twice a day, taken orally, over 48 weeks of therapy in human immunodeficiency virus-positive (HIV+) subjects with diarrhea.

Timeline

Start

2011-06-07

Primary completion

2012-10-31

Completion

2012-10-31

Drugs

Indications